Page last updated: 2024-09-03
ym 022 and dinoprostone
ym 022 has been researched along with dinoprostone in 1 studies
Compound Research Comparison
| Studies (ym 022) | Trials (ym 022) | Recent Studies (post-2010) (ym 022) | Studies (dinoprostone) | Trials (dinoprostone) | Recent Studies (post-2010) (dinoprostone) |
|---|---|---|---|---|---|
| 65 | 1 | 8 | 29,105 | 1,346 | 6,357 |
Protein Interaction Comparison
| Protein | Taxonomy | ym 022 (IC50) | dinoprostone (IC50) |
|---|---|---|---|
| Prostaglandin E2 receptor EP1 subtype | Homo sapiens (human) | 0.0155 | |
| Prostaglandin E2 receptor EP4 subtype | Homo sapiens (human) | 0.0031 | |
| Prostaglandin E2 receptor EP4 subtype | Rattus norvegicus (Norway rat) | 0.0021 | |
| Prostaglandin E2 receptor EP3 subtype | Homo sapiens (human) | 0.002 | |
| Prostaglandin E2 receptor EP2 subtype | Homo sapiens (human) | 0.0087 | |
| Prostacyclin receptor | Homo sapiens (human) | 0.26 | |
| Prostaglandin E2 receptor EP2 subtype | Rattus norvegicus (Norway rat) | 0.0052 |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Fox, JG; Lee, CW; Muthupalani, S; Rickman, B; Rogers, AB; Takaishi, S; Wang, TC; Yang, P | 1 |
Other Studies
1 other study(ies) available for ym 022 and dinoprostone
| Article | Year |
|---|---|
Combination of sulindac and antimicrobial eradication of Helicobacter pylori prevents progression of gastric cancer in hypergastrinemic INS-GAS mice.
Topics: Animals; Anti-Infective Agents; Antineoplastic Agents; Benzodiazepines; Blotting, Western; Cell Proliferation; Cyclooxygenase 1; Cyclooxygenase 2; Dinoprostone; Disease Models, Animal; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Hormone Antagonists; Hydrogen-Ion Concentration; Interferon-gamma; Male; Membrane Proteins; Mice; Precancerous Conditions; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms; Sulindac; Tumor Necrosis Factor-alpha | 2009 |